RxDoctor Payments Data

Yu Guan, MD

Family Medicine · Yorktown, VANPI 1801091236

Payments from drug & device makers

$11,986in general payments, 2019–2025

Across 733 payments — averaging $16.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$833
  • GSK$799
  • plus $5K from 38 others

What the payments were for

  • Food & beverage$11,83099%
  • Education$1561%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,986 in reported general payments places this provider in the 95th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$246,384
Medicare patients
358
Services billed
4,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$43,667
EliquisApixaban27$26,811
XareltoRivaroxaban15$25,372
MounjaroTirzepatide17$22,474
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$18,908
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$10,831
Atorvastatin Calcium225$1,908
Rosuvastatin Calcium71$1,852
SynthroidLevothyroxine Sodium35$1,805
Telmisartan45$1,611
Duloxetine Hcl30$1,447
Amlodipine Besylate200$1,329
Losartan Potassium166$1,294
Levothyroxine Sodium74$983
Escitalopram Oxalate81$960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,083$43,66722 claims
GSKTrelegy Ellipta, Anoro Ellipta$799$29,73927 claims
PfizerEliquis$590$26,81127 claims
Johnson & JohnsonXarelto$416$25,37215 claims
Lilly USA, LLCMounjaro$833$22,47417 claims
AbbVieSynthroid$1,638$1,80535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Yorktown

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →